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abstract
PURPOSE The optimum number of treatment courses for younger patients with acute myeloid leukemia (AML) is
uncertain. The United KingdomNational Cancer Research Institute AML17 trial randomly assigned patients who
were not high risk to a total of three versus four courses.
PATIENTS AND METHODS Patients received two induction courses based on daunorubicin and cytarabine (Ara-
C), usually with gemtuzumab ozogamicin. Following remission, 1,017 patients were randomly assigned to a third
course, MACE (amsacrine, etoposide, and Ara-C), plus a fourth course of MidAc (mitoxantrone and Ara-C) and
following an amendment to one or two courses of high-dose Ara-C. Primary end points were cumulative in-
cidence of relapse (CIR), relapse-free survival (RFS), and overall survival (OS). Outcomes were correlated with
patient characteristics, mutations, cytogenetics, induction treatments, and measurable residual disease (MRD)
postinduction.
RESULTS In logrank analyses, CIR and RFS at 5 years were improved in recipients of four courses (50% v
58%: hazard ratio [HR] 0.81 [0.69-0.97], P 5 .02 and 43% v 36%: HR 0.83 [0.71-0.98], P 5 .03, re-
spectively). While OS was not significantly better (63% v 57%: HR 0.84 [0.69-1.03], P 5 .09), the
noninferiority of three courses to four courses was not established. The impact on relapse was only sig-
nificant when the fourth course was Ara-C. In exploratory analyses, although MRD impacted survival, a
fourth course had no effect in either MRD-positive or MRD-negative patients. A fourth course was beneficial
in patients who lacked a mutation of FLT3 or NPM1, had, 3 mutations in other genes, or had a presenting
WBC of , 10 3 109 L21
CONCLUSION Although a fourth course of high-dose Ara-C reduced CIR and improved RFS, it did not result in a
significant OS benefit. Subsets including those with favorable cytogenetics, those lacking a mutation of FLT3 or
NPM1, or those with , 3 other mutations may derive survival benefit.
J Clin Oncol 00. © 2020 by American Society of Clinical Oncology
INTRODUCTION
A number of different induction schedules and
combinations given to patients with acute myeloid
leukemia (AML) will achieve morphological marrow
blast clearance in 75%-85% of younger patients,
arbitrarily defined as , 60 years of age.1-4 More
intensive combinations often only require a single
induction course.4 In remission, the risk of relapse is
based on several factors including presenting WBC
count, age, secondary disease, morphological re-
sponse of the bone marrow if not in remission, cy-
togenetics, and mutation analysis.5,6 More recently,
estimates of minimal residual disease (MRD)
assessed after the first or second induction course
have also been shown to be important for relapse
risk,7-9 although further data are required to establish
when the MRD status is predictive of what the op-
timal treatment should be. From the combined
prognostic information, patients will be regarded as
at high, intermediate, or low risk of relapse. Usually,
the issue requiring clarification is whether a stem cell
transplant should be recommended. Prospective
studies have now demonstrated that for patients who
have FLT3 mutation type 1 inhibitors, midostaurin10
but not lestaurtinib11 will reduce relapse risk and
improve survival. Other recently approved drugs may
deliver further reductions in relapse for particular
subgroups.
High-dose cytarabine (Ara-C) has been an established
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landmark study of Mayer et al,12 who showed that a higher
dose of 3 g/m2 was superior to 400 mg/m2 or 100 mg/m2
each for four courses after which four courses of mainte-
nance were given.
United Kingdom trials have tried to establish the optimum
number of consolidation courses since we explored giving
two versus six courses in AML8.13 In order to explore the
dose level of cytarabine and the total number of courses
required, in our consecutive Medical Research Council
(MRC) AML12 and 15 trials, we randomly assigned
. 1,300 patients between four and five courses of total
chemotherapy and established that adding a fifth course
(Ara-C 1.5 g/m2) provided no additional benefit.14,15 We also
demonstrated that patients randomly assigned to Ara-C 1.5
g/m2 for the third and fourth courses did not have a sig-
nificantly inferior survival outcome to those receiving Ara-C
3 g/m2, either overall or in any risk subgroup.15 We now
report the experience in the National Cancer Research
Institute AML17 trial, which compared three courses versus
four courses of total treatment for non–high-risk patients.
PATIENTS AND METHODS
The AML17 Trial
The United Kingdom MRC AML17 trial (ISRCTN55675535)
tested a number of interventions for induction, which have
already been reported.11,16-18 Briefly, patients of age from
18 years usually up to 60 years were initially randomly
assigned to receive ADE (Ara-C, daunorubicin, and eto-
poside) or DA (daunorubicin and Ara-C) for the first two
courses combined with gemtuzumab ozogamicin as a
single dose of 3 mg/m2 or 6 mg/m2 in course 1, in which
neither the addition of etoposide nor dosing of gemtuzumab
ozogamicin at 6 mg/m2 improved the result.18 In a sub-
sequent amendment, induction treatment was DA treat-
ment where the daunorubicin dose in course 1 was either
60 mg/m2 or 90 mg/m2. In this comparison, no overall
difference was found,4 but it later emerged that patients
with a FLT3mutation benefited from the dose of 90 mg/m2.19
Patients with high-risk myelodysplastic syndrome (defined
as. 10%marrow blasts), with de novo or secondary AML,
with any WHO performance score could be included, but
the blast transformation of chronic myeloid leukemia and
acute promyelocytic leukemia was excluded. After the first
course of induction treatment, patients were designated
as high-, intermediate-, or low-risk based on our validated
weighted risk score,5,6 which is based on the presenting
WBC count, age, cytogenetics, and secondary disease
and is presented in detail in the Protocol (online only).
High-risk patients were subjected to a separate random
assignment of FLAG-Ida (fludarabine, Ara-C, granulocyte
colony-stimulating factor, and idarubicin) versus DClo
(daunorubicin and clofarabine) with the intention to proceed
to transplantation, which has previously been reported,16
showing the superiority of FLAG-Ida in this setting.
Intermediate-risk patients with a FLT3mutation could enter
a random assignment of the addition of the FLT3 inhibitor,
lestaurtinib, or not, while other intermediate-risk patients
without the FLT3 mutation could be randomly assigned to
the addition of the mammalian target of Rapamicin in-
hibitor, everolimus, or not. The results of both interventions
have previously been reported with neither addition
showing overall benefit.11,17 After the two induction cour-
ses, all intermediate- and good-risk patients, whether re-
ceiving lestaurtinib or everolimus or not, were eligible to be
randomly assigned to have one or two consolidation
courses following the confirmation of remission (ie, three v
four courses of treatment in total). This random assignment
helped in recruiting patients from April 2009 to December
2014. Initially, until June 2010, the consolidation treatment
random assignment for the third and fourth courses was
between MACE (amsacrine, Ara-C, and etoposide) and
MACE plus MidAc (mitoxantrone and Ara-C) (n 5 120). In
light of the results of the previous MRC AML15 trial, which
CONTEXT
Key Objective
After two courses of induction treatment, patients who were in remission and not high risk were randomly assigned to one or
two more courses of treatment.
Knowledge Generated
Patients given two courses of high-dose cytarabine (ie, a total of four courses) had a reduced cumulative incidence of
relapse and an improved relapse-free survival but did not result in a significant benefit in overall survival.
The trial did not establish that three courses of chemotherapy were noninferior to the standard of care of four courses.
Although measurable residual disease (MRD) predicted the risk of relapse, overall administration of a fourth course had
no survival benefit on either MRD-positive or MRD-negative patients.
Relevance
This study contributes information to the question of how much chemotherapy is required for younger patients with acute
myeloid leukemia.
2 © 2020 by American Society of Clinical Oncology
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compared MACE/MidAc with two courses of Ara-C,15 a
subsequent protocol amendment changed the random
assignment to one versus two courses of high-dose Ara-C
(3 g/m2 twice a day days 1, 3, and 5) (n 5 897). Random
assignment took place after count recovery following the
second induction course. The aim of the three versus four
random assignment was to define if a fourth treatment
course was necessary and whether the treatments involved
were relevant. The trial flow diagram and details of drugs
used are shown in Fig 1.
Correlative Studies
Cytogenetic analyses were undertaken locally in laboratories
that participate in the national quality assurance scheme,
centrally reviewed, and classified according to our estab-
lished criteria.20 Mutation analysis of the FLT3 and NPM1
status was performed in a single reference lab. Although not
integral to therapeutic decisions in the trial, samples for
MRD, which were not disclosed to investigators, were col-
lected after each induction course and undertaken by flow
cytometry in one of the two reference labs by methods
previously described,8,21 and whole genome sequencing
(Sanger sequencing) as described elsewhere22 of additional
82 genes was undertaken on 443 stored samples from
participants in this random assignment at the Sanger Centre
(Cambridge, United Kingdom). The FLT3 mutation status
was provided during the trial to enable entry to the les-
taurtinib random assignment.
Patients were randomly assigned in 110 centers in the
United Kingdom, five in Denmark, and five in New Zealand.
The trial was sponsored by Cardiff University and approved
by the All Wales Research Ethics Committee on behalf of all
UK investigators, by the DanishMedicines Agency for sites in
Denmark, and by the New Zealand Medicines and Medical
Devices Safety Agency for sites in New Zealand.
Written consent was obtained for each random assignment
and for the storage of diagnostic samples. The trial was
conducted in accordance with the Declaration of Helsinki.
Statistical Considerations and End Points
The primary outcome measure for this random assignment
was overall survival (OS) at 5 years. It was anticipated that
about 55% of patients who entered the whole AML17 trial
would be available for the consolidation chemotherapy
random assignment. The trial was anticipated to detect,
with 90% power, a difference in survival from 55% to 65%,
equivalent to a hazard ratio (HR) of 0.71; a critical number
of 370 events was required to evaluate this difference. The
primary question was whether three courses were non-
inferior to four courses, at a one-sided significance of
0.025; consequently, effect sizes are reported with 95%
two-sided CIs throughout. Noninferiority would be con-
cluded if the lower 95% CI bound was above 0.71. Toxicity
(hematologic recovery times and nonhematologic toxicity)
was scored using the National Cancer Institute Common
Toxicity Criteria, Version 3, and resource use data (blood
product support, days on antibiotics, and hospitalization)
were collected. All end points were defined according to the
revised International Working Group criteria,23 where OS
and relapse-free survival (RFS) were measured from the
point of random assignment.
The analyses are by intention to treat. Categorical end points
(eg, OS) were compared using Mantel-Haenszel tests, giving
Peto odds ratios (ORs) and CIs. Continuous/scale variables
were analyzed by nonparametric (Wilcoxon rank-sum) tests.
Time-to-event outcomeswere analyzed using the logrank test,
with Kaplan-Meier survival curves. Analyses adjusted for
random assignment parameters are performed using the Cox
regression and given in parallel to the assumption-free logrank
approach. ORs/HRs, 1 indicate benefit for the extra course
of chemotherapy. All survival percentages are at 5 years
unless otherwise stated. The median follow-up at the time of
final analysis was 55.1 months (range, 1.2-99.4 months).
In addition to overall analyses, exploratory analyses were
performed stratified by the random assignment stratifica-
tion parameters and other important variables, including
correlations with MRD, with suitable tests for interaction.
Because of the well-known dangers of subgroup analysis,
these were interpreted cautiously.
RESULTS
Patient Characteristics
Between April 2009 and December 2014, a total of 1,709
patients, on recovery from induction course 2, were eli-
gible for this random assignment of whom 1,017 (60%)
were randomly assigned. The reasons for not being ran-
domly assigned were only listed as patient or clinician
preference. The interval between diagnosis and random
assignment was 2.6 months (range, 1.4-5.2 months).
Patients not entering the random assignment were gen-
erally similar but were less likely to be de novo AML, to
have worse cytogenetics, and to have received DA60 in
induction (Protocol); however, the OS at 5 years of those
eligible who reached the median time of random as-
signment but did not enter the random assignment was
60%, which was the same for those who were randomly
assigned (60%; P 5 .4). The characteristics and treat-
ments of the randomly assigned patients are shown in
Table 1. There were no differences between those ran-
domly assigned with respect to age, sex, performance
score, presenting WBC count, cytogenetic risk group,
NPM1 status, induction treatments, and risk score or
number given stem cell transplant overall or in CR1. There
was a modest difference in 479 patients whose MRD
status was known after course 1 or in 365 randomly
assigned patients whose MRD status was known after
course 2, with fewer patients allocated to three courses to
be MRD-negative. As previously stated, the MRD status of
patients was not made available to investigators. There
was no difference in the frequency of mutations or in the
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Schedule Any limitations Details
ADE Daunorubicin 50 mg/m
2 d 1,3,5; Ara-C 100mg/m2 every 12 hours d 1-10(c1), d1-8
(c2), Etoposide 100 mg/m2 d1-5 
DA 90 mg† Until October 2013 Daunorubicin 90 mg/m
2 d 1,3,5; Ara-C 100mg/m2 every 12 hours d 1-10 (c1),
d1-8 (c2)
DA 60mg Daunorubicin 60 mg/m
2 d 1,3,5; Ara-C 100mg/m2 every 12 hours d 1-10 (c1), d1-8
(c2)
m/gm3 nicimagozO bamuzutmeGOG 2 given on day 1 of course 2 of chemotherapy
CEP-701* Until 22 Oct 2012
Lestaurtinib (CEP-701) 40-80mg bd (depending on azole antifungals) from 2 days
postchemo to 2 days presubsequent course, up to a maximum of 28 days 
mTOR** Until 12 Oct 2012
Everolimus 5-10 mg/day, from 2 days postchemo to 2 days presubsequent course,
up to a maximum of 28 days 
D Clofarabine*** Until 3 Dec 2012 Daunorubicin 50 mg/m2 d 1,3,5; Clofarabine 20mg/m2 d 1-5 
FLAG-Ida Fludarabine 30 mg/m
2 (d 2-6); Ara-C 2g/m2 (4h post fludarabine), d 2-6; G-CSF
263 g s.c. d 1-7
MACE Until June 2010 Cytarabine 200mg/m2 d1-5; Amsacrine 100mg/m2 d1-5, Etoposide 100mg/m2 d1-5
MidAc Until June 2010 Mitoxantrone 10mg/m2 d1-5, cytarabine 1g/m2 twice a day d1-3
Ara-C From June 2010 Ara-C 3 g/m2 12-hourly, d1, 3, 5.
Protocol Version 7
FIG 1. Protocol flow diagram. *Following closure of the CEP-701 randomly assigned, patients were guided by risk score to either poor risk
or nonpoor risk options. **Following closure of the mTOR inhibition random assignment, patients in this group received DA 50mg alone.
***Following closure of the D Clofarabine arm, patients were recommended to receive FLAG-Ida (which was also the case if renal criteria
were not met). †Following closure of the high-dose daunorubicin arm, patients were allocated DA60. ADE, Ara-C, daunorubicin, and
etoposide; APL, acute promyelocytic leukemia; CBF, core binding factor; DA, daunorubicin and Ara-C; FLAG-Ida, fludarabine, Ara-C,
granulocyte colony-stimulating factor, and idarubicin; GO, gemtuzumab ozogamicin; MACE, amsacrine, etoposide, and Ara-C; MidAc,
mitoxantrone and Ara-C; mTor, mammalian target of Rapamicin.
4 © 2020 by American Society of Clinical Oncology
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MACE/MidAc 58 (11%) 62 (12%)
Ara-C 452 (89%) 445 (88%)
Age
16-29 68 (13%) 66 (13%)
30-39 70 (14%) 71 (14%)
40-49 150 (29%) 148 (29%)
50-59 162 (32%) 164 (32%)




Female 274 (54%) 282 (56%)
Male 236 (46%) 225 (44%)
Diagnosis
De novo 488 (96%) 486 (96%)
Secondary 6 (1%) 8 (2%)
MDS 16 (3%) 13 (3%)
WHO PS
0 364 (71%) 365 (72%)
1 124 (24%) 124 (24%)
2 12 (2%) 12 (2%)
3 10 (2%) 5 (1%)
4 0 1 (,0.5%)
WBC
0-9.9 258 (51%) 247 (49%)
10-49.9 192 (38%) 180 (36%)
50-99.9 43 (8%) 52 (10%)




Favorable 119 (24%) 115 (24%)
Intermediate 369 (75%) 371 (76%)
Adverse 1 (,0.5%) 1 (,0.5%)
Unknown 21 20
FLT3 ITD
WT 397 (83%) 399 (83%)
Mutant 79 (17%) 83 (17%)
Unknown 34 25
NPM1c
WT 289 (62%) 288 (60%)
Mutant 178 (38%) 190 (40%)
Unknown 43 29
(continued in next column)







WT 422 (89%) 443 (92%)




18 (4%) 16 (3%)
ADE 42 (8%) 45 (9%)
ADE1GO3 33 (6%) 31 (6%)
ADE1GO6 35 (7%) 33 (7%)
DA1GO3 35 (7%) 34 (7%)
DA1GO6 34 (7%) 35 (7%)
DA 90 mg 94 (18%) 96 (19%)
DA 60 mg 91 (18%) 90 (18%)
DA 60 mg (nonrandomized) 128 (25%) 127 (25%)
Lestaurtinib random assignment 68 (13%) 68 (13%)
Lestaurtinib 45 45
No lestaurtinib 23 23
Everolimus random assignment 114 (22%) 113 (22%)
Everolimus 76 77
No everolimus 38 36
Post Course 1 Risk Score
Good risk 130 (26%) 136 (27%)
Standard risk 377 (74%) 369 (73%)
Unknown 3 2
MRD status post course 1
CR, MRD-negative 95 (40%) 117 (48%)
CR, MRD-positive 128 (54%) 116 (48%)
No CR 12 (5%) 11 (5%)
Unknown 275 263
MRD status post C2
MRD-negative 113 (64%) 139 (74%)
MRD-positive 64 (36%) 49 (26%)
Not known 333 319
Transplanted 191 (37%) 164 (32%)
Any allograft 153 (30%) 142 (28%)
Any transplant in CR1 37 (7%) 42 (8%)
Allograft in CR1 29 (6%) 39 (8%)
Abbreviations: ADE, Ara-C, daunorubicin, and etoposide; CR,
complete remission; DA, daunorubicin and Ara-C; GO, gemtuzumab
ozogamicin; ITD, internal tandem duplication; MACE, amsacrine,
Ara-C, and etoposide; MDS, myelodysplatic syndrome; MidAc,
mitoxantrone and Ara-C; MRD, measurable residual disease; PS,
performance score; TKD, tyrosine kinase domain; WT, wild type.
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numbers of patients with different numbers of mutations
detected. The deployment of patients is shown in Fig 2.
Although the addition of a fourth course significantly re-
duced the cumulative incidence of relapse (CIR) and RFS,
the OS difference at 5 years failed to reach significance.
CIR and RFS
Overall, those allocated to the fourth course had a significantly
lower CIR: 50% v 58% (raw HR 0.81 [0.69-0.97], P 5 .02;
adjusted HR 0.82 [0.69-0.97], P 5 .02) (Data Supplement
and Fig 3A). With respect to the treatment received, there was
no significant interaction. While the effect on CIR was only
significant with Ara-C as the fourth course (Figs 3B-3C), effect
sizes are similar (0.82 [0.49-1.38]MACE/MidAc, v0.81 [0.68-
0.98] Ara-C). Similarly, while the effect appeared stronger in
favorable-risk patients (0.67 [0.45-1.02]) than those with
intermediate cytogenetics (0.90 [0.74-1.10]), there was no
significant interaction (P 5 .2, Figs 3D-3E).
Overall RFS differences, by treatment and risk groups,
showed the same differences as CIR (Protocol), namely that
there was benefit in a fourth course with respect to pre-
vention of relapse.
Treatment Compliance
Of the 507 patients allocated to four courses, 74% received
all intended courses, which resulted in a 67% survival,
whereas for those allocated four but who only received
three, survival was 54% (P5 .002; HR, 0.58 [0.040-0.84]).
The recipients of four courses required a median time of an
extra 23 days of hospitalization, 9 days on antibiotics, 5.6
and 5.9 units of RBCs and platelets and 4 and 5 weeks for
recovery of neutrophils and platelets, and had a 2% risk of
death within 60 days.
OS
There was a nonsignificant difference in favor of four courses
(63% v 56%) with respect to survival (Fig 4A). Considering
the question of whether three courses were noninferior to four
courses, the CI in both unadjusted and adjusted analyses
crosses the threshold of 0.71, meaning that there is no ev-
idence to conclude noninferiority at this threshold. In spite of
the reduced CIR, there was no detectable survival difference
in patients treated in theMACE/MidAc arm (Fig 4B), but there
were nonsignificant differences in favor of four courses in
patients treated in the Ara-C arms in both risk groups (Figs
4C-4E). If the 79 patients who received a transplant in CR1
are censored at transplant, the survival rates are 63% for
three courses and 72% for four courses. The overall out-
comes are summarized in the Protocol.
Exploratory Subgroup Analyses
The outcome was not affected by any of the patients’ char-
acteristics or induction treatments (Protocol), although those
presentingwith a lowWBCof, 10.03 109/L had a significant
benefit from four courses. MRD information was obtained
after course 1 in 456 patients and in 365 patients after course
2. The OS at 5 years in patients who were MRD-negative after
the first or second induction courses (n 5 464) at 73% was
better than that in the MRD-positive patients (n 5 357) at
50%. In patients who were assessed after course 1 of in-
duction, the OS was not significantly different between the
treatment arms, irrespective of the MRD status (Figs 5A-5B).
In patients with MRD information after course 2, the OS was
69% if MRD-negative and 37% if MRD-positive, but again
there was no significant difference in either groups if allocated
to three or four courses (Figs 5C-5D).
Although there appears to be a significant advantage of four
courses in patients who received daunorubicin 90mg/m2 in
induction (Protocol), the test for heterogeneity was not
significant, suggesting that any apparent benefit is not
conclusive.
Four courses were significantly beneficial in patients
without an FLT3 internal tandem duplication or tyrosine
kinase domain or NPM1 mutation or in 92 of the 433
patients with , 3 mutations as detected using Sanger
sequencing (Fig 6). The benefit appeared greatest in pa-
tients with FLT3/NMP1 wild type, although there was no
significant interaction. For the purpose of assessing the
prognostic value of the mutations detected using Sanger
sequencing, only mutations that occurred in more than 20
of the 433 patients were considered, but no correlations
were observed (Protocol).
3,215 adult non-APL patients
enter AML17 6/4/09 and
31/12/2014
1,709 patients eligible for
mTOR inhibition
random assignment
215 patients die by day 60
7 patients withdrawn
by day 60
1,111 high risk by score or
genotype
173 not in CR post C2
1,017 randomized
692 elect to not randomize
(patient/clinician preference)
507 allocated 4 courses510 allocated 3 courses
FIG 2. CONSORT diagram. AML, acute myeloid leukemia; APL, acute
promyelocytic leukemia; CR, complete remission; mTor, mammalian
target of Rapamicin.
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AML17: CIR 3 v 4 courses
MACE/MidAC v MACE
0 1 2 3 4 5 6 7 8 9 10




57 33 24 23 22 19 17 12 0 0 0
62 38 32 31 27 26 22 12 0 0 0

































HR 0.81 (0.69−0.97), P = ·02
0 1 2 3 4 5 6 7 8 9 10
Years From random assignment
504 303 218 147 105 63 29 12 0 0 0






























AML17: CIR 3 v 4 courses
Favorable
















118 79 64 41 30 18 9 5 0 0 0
At risk:
3 courses
4 courses 113 85 75 60 37 26 9 3 0 0 0

















AML17: CIR 3 v 4 courses





HR 0.81 (0.68−0.98), P = ·03
0 1 2 3 4 5 6 7 8 9 10
Years From random assignment
447 270 194 124 83 44 12 0 0 0 0






























AML17: CIR 3 v 4 courses
Intermediate















365 215 148 103 72 42 18 6 0 0 0
At risk:
3 courses
4 courses 368 220 167 122 85 42 23 10 0 0 0
HR 0.90 (0.74−1.10), P = ·3
E
FIG 3. Cumulative incidence of relapse. AML, acute myeloid leukemia; HR, hazard ratio; MidAc, mitoxantrone and Ara-C.
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AML17: Survival 3 v 4 courses
MACE/MidAC v MACE
0 1 2 3 4 5 6 7 8 9 10





3 courses 58 51 42 36 35 32 27 22 1 0 0
4 courses 62 48 42 40 36 34 28 17 0 0 0



























HR 0.84 (0.69−1.03), P = ·09
0 1 2 3 4 5 6 7 8 9 10
Years From random assignment
510 434 344 237 174 110 49 22 1 0 0






























AML17: Survival 3 v 4 courses
Favorable











3 courses 119 113 97 64 47 32 16 8 0 0 0
4 courses 115 106 99 81 54 37 17 5 0 0 0



















AML17: Survival 3 v 4 courses




HR 0.81 (0.65−1.01), P = ·06
0 1 2 3 4 5 6 7 8 9 10
Years From random assignment
452 383 302 201 139 78 22 0 0 0 0




























AML17: Survival 3 v 4 courses
Intermediate









370 307 235 163 118 71 30 13 1 0 0
At risk:
3 courses
4 courses 371 302 248 182 126 68 34 13 0 0 0
HR 0.87 (0.70−1.09), P = ·2
E
FIG 4. Overall survival. AML, acute myeloid leukemia; HR, hazard ratio; MidAc, mitoxantrone and Ara-C.
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DISCUSSION
The recent approvals of new drugs for AML may move the
treatment algorithm in the relevant subgroups. However, it is yet
to be established for some of these new drugs whether com-
bination with standard chemotherapy may be their optimal
use.24 It therefore remains important to define the optimal total
treatment with chemotherapy that is required. There has been
extensive effort to establish the best agent and doses for in-
duction, but less attention to the dose and number of courses
of postinduction treatment. Recruiting sufficiently large num-
bers to reliably answer questions at this stage of treatment
is a logistical challenge. Definitive studies 25 years ago estab-
lished high-dose Ara-C as the standard of care for up to four
courses at a dose level of 3 g/m2. The MRC AML15 trial
(ISRCTN17161961) established that our previous standard of
care (MACE plus MidAC) was superior to high-dose Ara-C in
adverse-risk patients.15 There was little survival difference be-
tween 3 g/m2 and 1.5 g/m2 Ara-C dose levels. The addition of a
fifth course was tested in theMRCAML12 and 15 trials14,15 with
no evidence of benefit for a fifth course. A number of collab-
orative group trials have assessed the number of courses
without providing a universally accepted conclusion.25-27
In this trial, random assignment took place after the
completion of two induction courses and 1,709 (53%)
of the original trial entrants were eligible. In the intent-to-
treat analysis of the 1,017 patients randomly assigned, it
emerged that the addition of the fourth course significantly
reduced the CIR and significantly improved the RFS, but
the trend for better OS was not significant. This was the
case in the 885 patients who received exclusively Ara-C.
Because of carry over random assignment from our AML15
trial, 120 patients received MACE or MACE plus MidAc
among whom there was a similar trend for reduction in CIR
and improvement in RFS, but neither of which reached
statistical significance. Although the numbers become too
small for confidence, the benefit (CIR and RFS) of the
fourth course is more obvious in the favorable-risk group. In
terms of OS, based on the number of patients assessable,
AML17: Survival 3 v 4 courses





HR 0.77 (0.45−1.31), P = ·3
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A AML17: Survival 3 v 4 courses
MRD + course 1










128 98 76 50 35 23 11 5 0 0 0
116 92 77 51 34 21 6 1 0 0 0
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Years From random assignment
FIG 5. Effect of measurable residual disease (MRD). MRD, measurable residual disease; HR, hazard ratio.
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there is a strong trend for benefit in the recipients of Ara-C,
but not for the recipients of MACE/MidAC.
Among the several subgroups examined where a significant
difference was observed in conjunction with a test for
heterogeneity, which reached significance, were patients
who lacked a FLT3 or NPM1mutation, patients with one or
two mutations compared with . 2, and patients with
presenting WBCs of , 10 3 109/L. Patients who were
MRD-negative (at a level of 1 in 104) after course 1 or 2 had
a significantly better survival than those who were positive
at either time point, but the addition of a fourth course was
not beneficial in either group. In general, patients with more
favorable characteristics appear to benefit from a fourth
course, but only when high dose Ara-C consolidation is
used, whereas those with intermediate-risk characteristics
do not, although these were only trends for benefit.
There was a price to pay for the fourth course with respect




Events/Patients Statistics O.R. & 95% CI
(4 courses : 3 courses)
By FLT3 ITD mutation:
WT 0.71 (0.56, 0.89)




Test for heterogeneity between subgroups: 21 = 5·5; P = ·02 
By NPM1 mutation:
WT 0.71 (0.55, 0.92)




Test for heterogeneity between subgroups: 21 = 2·6; P = ·1; NS
By FLT3−ITD, NPM1 mutation:
ITD WT, NPM1 WT 0.65 (0.49, 0.86)
ITD WT, NPM1 Mutant 0.90 (0.58, 1.41)
ITD Mutant, NPM1 WT 1.06 (0.49, 2.29)




Test for heterogeneity between subgroups: 23 = 5·8; P = ·1; NS
By FLT3 TKD mutation:
WT 0.79 (0.64, 0.99)




Test for heterogeneity between subgroups: 21 = 0·4; P = ·5; NS
By number of mutations:
1−2 mutations 0.31 (0.14, 0.69)
3 mutations 1.47 (0.75, 2.87)
4 mutations 0.70 (0.36, 1.36)
5 mutations 0.98 (0.48, 1.99)





















































































2P = ·3; NS
Test for heterogeneity between subgroups: 24 = 9·6; P = ·05






FIG 6. Analysis stratified by mutation status. AML, acute myeloid leukemia; ITD, internal tandem duplication; OR,
odds ratio; TKD, tyrosine kinase domain; WT, wild type.
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support although there were no excessive deaths in re-
mission. However, as a consequence of the greater number
of relapses, more salvage transplants were required in
patients receiving just three courses (Table 1). It could be
speculated that the most useful interaction will eventu-
ally be the initial discrimination based on the MRD status
after the first or second induction course, where there
may be little benefit in a fourth course for those who are
MRD-positive, but benefit for those who are negative, or
vice versa.
Overall, this experience suggests that if Ara-C is the chosen
consolidation treatment, a fourth course of overall treat-
ment is probably beneficial. In a retrospective analysis of
the induction in the AML15 trial,15 patients who received
two courses of FLAG-Ida as induction without consolidation
had a similar survival to control patients who received two
induction courses of DA treatment followed by two courses
of consolidation. These were nonrandomized data and are
currently being tested in the ongoing AML19 trial
(ISRCTN78449203).
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Good risk 337 135 239·8
Standard risk 1359 787 844·1




FIG A1. Patients’ score derived from multiplying each relevant characteristic by the value derived from the Cox model: 0.01325*age (in years) 1
0.16994*sex (1 5 male, 0 5 female) 1 0.22131*diagnosis (1 5 de novo, 2 secondary) 1 0.65082*cytogenetics (1 5 favorable, 2 5 intermediate,
3 adverse)1 0.19529*status post C1 (15 complete remission, 25 partial remission, 35 no response)1 0.00169* WBC (x109/l). Distribution of patients
in MRC AML10,12 trials by index: Taking into account the apparent bimodality of the curve, patients with an index of 2 or below were deemed good risk, and
the data were arbitrarily divided at the 75th centile between standard and poor risk. Survival index from complete remission in AML10,12 according to the
risk groups was validated on data from MRC AML15 Trial.5
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FIG A2. Relapse-free survival (RFS). CR, complete remission.
© 2020 by American Society of Clinical Oncology
Burnett et al
Downloaded from ascopubs.org by UNIVERSITY LIVERPOOL on January 14, 2021 from 154.059.124.102









OR & 95% CI




Subtotal: 305/504 0.83 (0.71, 0.98)
2P = .03
Test for heterogeneity between subgroups: χ2
1




Subtotal: 0.87 (0.73, 1.03)
2P = .1; NS
Test for heterogeneity between subgroups: χ2
1
 = 1.6; P = .2; NS




Subtotal: 0.91 (0.71, 1.16)
2P = .4; NS
Test for heterogeneity between subgroups: χ2
2
 = 6.3; P = .04
Test for trend between subgroups: χ2
1
 = 2.4; P = .1; NS





















































−4.9 0.91 (0.69, 1.19)
2P = .5; NS
Test for heterogeneity between subgroups: χ2
1










143.3 0.83 (0.71, 0.98)
0.1 1.0






FIG A3. Stratified analysis of relapse-free survival. CR, complete remission; MRD, measurable residual disease.
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OR & 95% CI
(4 courses : 3 courses)
25/62 25/58 0.3 12.4 1.02 (0.59, 1.78)
ara−C 147/444 177/452 −17.1 80.9 0.81 (0.65, 1.01)
172/506 202/510 −16.8 93.3 0.84 (0.68, 1.02)
2P = .08
Test for heterogeneity between subgroups: χ21 = 0.6; P = .4; NS
14/65 23/68 −4.3 9.2 0.62 (0.33, 1.19)
23/71 20/70 1.8 10.7 1.19 (0.65, 2.16)
42/148 58/150 −10.3 24.9 0.66 (0.45, 0.98)
68/164 73/162 −2.1 35.1 0.94 (0.68, 1.31)
25/58 28/60 −1.1 13.2 0.92 (0.54, 1.58)
172/506 202/510 −15.9 93.2 0.84 (0.69, 1.03)
2P = .1; NS
Test for heterogeneity between subgroups: χ24 = 4.1; P = .4; NS
Test for trend between subgroups: χ21 = 0.5; P = .5; NS
100/281 104/274 −2.4 51.0 0.95 (0.72, 1.25)
72/225 98/236 −14.0 42.1 0.72 (0.53, 0.97)
172/506 202/510 −16.4 93.1
0.84 (0.68, 1.03)
2P = .09
Test for heterogeneity between subgroups: χ21 = 1.9; P = .2; NS
78/246 116/258 −21.0 48.4 0.65 (0.49, 0.86)
57/180 61/192 −0.3 29.4 0.99 (0.69, 1.42)
22/52 17/43 1.7 9.7 1.19 (0.64, 2.24)
15/28 8/17 1.8 5.6 1.37 (0.60, 3.14)
172/506 202/510 −17.8 93.1
0.83 (0.67, 1.01)
2P = .07
Test for heterogeneity between subgroups: χ23 = 6.5; P = .09
Test for trend between subgroups: χ21 = 6.1; P = .01
126/364 143/364 −9.1 67.1 0.87 (0.69, 1.11)
38/124 48/124 −6.2 21.4 0.75 (0.49, 1.14)
5/12 4/12 0.8 22.3 1.04 (0.68, 1.57)
3/6 7/10 −1.4 2.4 0.56 (0.16, 1.96)
172/506 202/510 −15.9 113.2
0.87 (0.72, 1.04)
2P = .1; NS
Test for heterogeneity between subgroups: χ23 = 1.7; P = .6; NS
Test for trend between subgroups: χ21 = 0.0; P = .9; NS
162/485 193/488 −17.2 88.5 0.82 (0.67, 1.01)
4/8 2/6 0.8 1.5 1.68 (0.34, 8.40)
6/13 7/16 0.3 3.2 1.10 (0.37, 3.28)
172/506 202/510 −16.1 93.2
0.84 (0.69, 1.03)
2P = .09
Test for heterogeneity between subgroups: χ22 = 1.0; P = .6; NS
15/115
Unstratified
24/119 −4.1 94.8 0.96 (0.78, 1.17)
149/371 168/370 −10.8 79.2 0.87 (0.70, 1.09)
164/486 192/489 −14.9 173.9
0.92 (0.79, 1.06)
2P = .3; NS
Test for heterogeneity between subgroups: χ21 = 0.4; P = .5; NS
172/506 202/510 −16.7 93.3 0.84 (0.68, 1.02)
0.1







FIG A4. Stratified analysis of overall survival.
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4 courses 3 courses
Statistics
(O−E) Var.
OR & 95% CI
(4 courses : 3 courses)
ADE alone (not rand) 7/16 8/18 −0.2 3.7 0.95 (0.34, 2.61)
ADE Alone 18/45 18/42 −0.7 9.0 0.92 (0.48, 1.77)
ADE+ GO 3mg 9/31 14/33 −2.5 5.7 0.65 (0.29, 1.47)
ADE + GO 6mg 13/33 19/35 −2.9 8.0 0.70 (0.35, 1.40)
DA + GO 3mg 17/34 16/35 1.2 8.2 1.15 (0.58, 2.28)
DA + GO 6mg 14/35 18/34 −2.6 7.7 0.71 (0.35, 1.45)
DA (60mg) − protocol 7 33/95 27/94 3.4 15.0 1.26 (0.76, 2.08)
DA (90mg) − protocol 7 25/90 38/91 −8.0 15.7 0.60 (0.37, 0.98)
DA 60mg − not rand. 36/126 43/128 −2.9 19.4 0.86 (0.55, 1.34)
Subtotal: 172/505 201/510 −15.3 92.3 0.85 (0.69, 1.04)
2P = .1; NS
Test for heterogeneity between subgroups: χ28 = 6.0; P = .6; NS
28/117 27/95 −3.5 13.4 0.77 (0.45, 1.31)
50/116 60/128 −3.2 27.2 0.89 (0.61, 1.29)
Not in remission
Confirmed CR MRD +
Confirmed CR MRD–
6/11 4/12 2.1 2.3 2.42 (0.67, 8.68)
Subtotal: 84/244 91/235 −4.7 43.0 0.90 (0.66, 1.21)
2P = .5; NS
Test for heterogeneity between subgroups: χ22 = 2.6; P = .3; NS
Test for trend between subgroups: χ21 = 1.5; P = .2; NS
MRD −ve 38/139 37/113 −4.5 18.4 0.78 (0.50, 1.24)
MRD +ve 28/49 36/64 0.3 15.6 1.02 (0.62, 1.68)
Subtotal: 66/188 73/177 −4.1 34.0 0.89 (0.63, 1.24)
2P = .5; NS
Test for heterogeneity between subgroups: χ21 = 0.6; P = .4; NS








Effect 2P = .08
By course 2 status:
By course 1 status:
By induction therapy:
FIG A5. Analysis stratified by prior treatment and MRD status. CR, complete remission; MRD, measurable residual disease.
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FIG A6. Sanger sequencing.
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4 courses 3 courses
Statistics
(O−E) Var.
OR & 95% CI
(4 courses : 3 courses)
Wild type 76/163 41.7 0.79 (0.59, 1.07)
Mutant 39/57 35/56 3.4 18.4 1.20 (0.76, 1.90)
Test for heterogeneity between subgroups: χ21 = 2.2; P = .1; NS
Wild type 94/185 −7.2 49.7 0.87 (0.66, 1.14)
Mutant 21/35 21/35 0.6 10.5 1.06 (0.58, 1.94)
Test for heterogeneity between subgroups: χ21 = 0.4; P = .6; NS
Wild type 93/185 −7.8 51.9 0.86 (0.65, 1.13)
Mutant 22/35 11/20 0.5 7.5 1.07 (0.52, 2.20)





120/205 −6.0 54.5 0.90 (0.69, 1.17)
Mutant 16/31 6/13 0.3 4.5 1.08 (0.43, 2.71)
Test for heterogeneity between subgroups: χ21 = 0.1; P = .7; NS
Wild Type 107/200 111/195 −3.2 54.4 0.94 (0.72, 1.23)
Mutant 8/20 15/23 −3.6 5.7 0.53 (0.23, 1.21)
Test for heterogeneity between subgroups: χ21 = 1.7; P = .2; NS
Wild Type 107/201 117/196 −7.9 55.8 0.87 (0.67, 1.13)
Mutant 8/19 9/22 0.6 4.2 1.15 (0.44, 3.01)
Test for heterogeneity between subgroups: χ21 = 0.3; P = .6; NS
Wild Type 101/199 112/200 −5.9 53.2 0.90 (0.68, 1.17)
Mutant 14/21 14/18 6.9 0.82 (0.39, 1.73)
Test for heterogeneity between subgroups: χ21 = 0.1; P = .8; NS
Wild Type 102/197 114/203 −4.1 53.9 0.93 (0.71, 1.21)
Mutant 13/23 12/15 5.5 0.49 (0.21, 1.13)
Test for heterogeneity between subgroups: χ21 = 2.0; P = .2; NS
Wild Type 106/206 110/199 −4.5 53.9 0.92 (0.70, 1.20)
Mutant 9/14 16/19 −2.2 5.7 0.68 (0.30, 1.55)
Test for heterogeneity between subgroups: χ21 = 0·5; P = ·5; NS
Wild Type 105/204 118/202 −8.7 55.6 0.86 (0.66, 1.11)
Mutant 10/16 8/16 2.1 4.4 1.60 (0.63, 4.06)
Test for heterogeneity between subgroups: χ21 = 1.6; P = .2; NS





−0.5 2.5 0.82 (0.24, 2.85)
Test for heterogeneity between subgroups: χ21 = 0.0; P = .9; NS
Wild Type 108/208 114/204 −3.3 55.4 0.94 (0.72, 1.23)
Mutant 7/12 12/14 −4.1 4.5 0.40 (0.16, 1.01)
Test for heterogeneity between subgroups: χ21 = 3.0; P = .08
Wild Type 109/209 120/207 −7.0 57.1 0.88 (0.68, 1.15)
Mutant 6/11 6/11 0.2 3.0 1.07 (0.34, 3.33)















Wild Type 113/209 123/207 −5.2 58.9 0.92 (0.71, 1.18)
Mutant 21/1 3/11 −0.9 1.2 0.45 (0.08, 2.71)
Subtotal: 115/220 −6.3 60.1
Subtotal: 115/220 −6.6 60.1




Subtotal: 115/220 126/218 −5.7 59.1
Subtotal: 115/220 126/218 −6.9 60.1
Subtotal: 115/220 126/218 −7.3 60.0
Subtotal: 115/220 126/218 −7.2 60.0
Subtotal: 115/220 126/218 −8.0 59.4
Subtotal: 115/220 126/218 −6.6 59.6
Subtotal: 115/220 126/218 −6.6 60.0
Subtotal: 115/220 126/218 −6.4 60.1
Subtotal: 115/220 126/218 −7.5 59.9
Subtotal: 115/220 126/218 −6.8 60.1
Subtotal: 115/220 126/218 −6.1 60.1
0.90 (0.70, 1.16)
2P = .4; NS
0.90 (0.70, 1.15)
2P = .4; NS
0.88 (0.69, 1.14)
2P = .3; NS
0.91 (0.70, 1.17)
2P = .5; NS
0.89 (0.69, 1.15)
2P = .4; NS
0.89 (0.69, 1.14)
2P = .3; NS
0.89 (0.69, 1.14)
2P = .4; NS
0.87 (0.68, 1.13)
2P = .3; NS
0.89 (0.69, 1.15)
2P = .4; NS
0.90 (0.70, 1.15)
2P = .4; NS
0.90 (0.70, 1.16)
2P = .4; NS
0.88 (0.69, 1.14)
2P = .3; NS
0.89 (0.69, 1.15)
2P = .4; NS
0.90 (0.70, 1.16)
2P = .4; NS






FIG A7. Analysis stratified by Sanger sequencing.
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TABLE A1. Patient Characteristics of Those Eligible by Entry to Random Assignment (n 5 1017) or Not (n 5 692)back
Characteristic Randomly Assigned (n 5 1017) Not Randomly Assigned (n 5 692) P
Treatmenta .08
MACE/MidAc 120 (12%) 63 (9%)
Ara-C 897 (88%) 629 (91%)
Age .2
16-29 134 (13%) 100 (14%)
30-39 141 (14%) 104 (15%)
40-49 298 (29%) 154 (22%)
50-59 326 (32%) 207 (30%)




Female 556 (55%) 378 (55%)
Male 461 (45%) 314 (45%)
Diagnosis , .001
De novo 974 (96%) 618 (89%)
Secondary 14 (1%) 33 (5%)
MDS 29 (3%) 41 (6%)
WHO PS .9
0 729 (72%) 480 (69%)
1 248 (24%) 193 (28%)
2 24 (2%) 12 (2%)
3 15 (1%) 7 (1%)
4 1 (, 0.5%) 0
WBC .7
0-9.9 505 (50%) 381 (55%)
10-49.9 372 (37%) 204 (29%)
50-99.9 95 (9%) 62 (9%)




Favourable 234 (24%) 94 (15%)
Intermediate 740 (76%) 498 (80%)
Adverse 2 (, 0.5%) 27 (4%)
Unknown 41 73
FLT3 ITD .01
WT 796 (83%) 485 (78%)
Mutant 162 (17%) 137 (22%)
Unknown 59 70
NPM1c .5
WT 577 (61%) 388 (63%)
Mutant 368 (39%) 229 (37%)
Unknown 72 75
(continued on following page)
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TABLE A1. Patient Characteristics of Those Eligible by Entry to Random Assignment (n 5 1017) or Not (n 5 692)back (continued)
Characteristic Randomly Assigned (n 5 1017) Not Randomly Assigned (n 5 692) P
FLT3 TKD .2
WT 865 (91%) 575 (93%)
Mutant 88 (9%) 45 (7%)
Unknown 64 72
Induction chemotherapy .006
ADE (not randomly assigned) 34 (3%) 22 (3%)
ADE 87 (9%) 39 (6%)
ADE 1 GO3 64 (6%) 48 (7%)
ADE 1 GO6 68 (7%) 31 (4%)
DA 1 GO3 69 (7%) 39 (6%)
DA 1 GO6 69 (7%) 43 (6%)
DA 90 mg 190 (19%) 111 (16%)
DA 60 mg 181 (18%) 128 (19%)
DA 60 mg (not randomly assigned) 255 (25%) 231 (33%)
Abbreviations: ADE, Ara-C, daunorubicin, and etoposide; DA, daunorubicin and Ara-C; MACE, amsacrine, Ara-C, and etoposide; ITD, internal tandem
duplication; MDS, myelodysplastic syndrome; TKD, tyrosine kinase domain; WT, wild type.
aTreatment is imputed for those not entering the random assignment based on entry to trial (what would have been the option at that stage).
TABLE A2. Clinical Outcomes by Treatment Armback
End Point 3 Courses, % 4 Courses, % Unadjusted HR and CI P Adjusted HR and CI Adjusted P
5-year cumulative incidence of relapse 58 50 0.81 (0.69 to 0.97) .02 0.82 (0.69 to 0.97) .02
5-year cumulative incidence of death in CR 6 6 1.04 (0.62 to 1.75) .9 1.03 (0.61 to 1.73) .9
5-year RFS 36 43 0.83 (0.71 to 0.98) .03 0.84 (0.71 to 0.99) .03
5-year OS 57 63 0.84 (0.69 to 1.03) .09 0.84 (0.69 to 1.03) .10
5-year survival postrelapse 31 34 0.93 (0.74 to 1.16) .5 0.92 (0.74 to 1.15) .5
5-year OS censored at SCT 63 72 0.85 (0.66 to 1.10) .2 0.86 (0.66 to 1.12) .3
Abbreviations: CR, complete remission; OS, overall survival; RFS, relapse-free survival; SCT, stem-cell transplantation.
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